Compare ADUS & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADUS | SRPT |
|---|---|---|
| Founded | 1979 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.5B |
| IPO Year | 2009 | 2000 |
| Metric | ADUS | SRPT |
|---|---|---|
| Price | $94.48 | $21.58 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 29 |
| Target Price | ★ $135.40 | $25.85 |
| AVG Volume (30 Days) | 204.3K | ★ 3.3M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.40 | N/A |
| EPS | ★ 5.22 | N/A |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $4.64 | N/A |
| P/E Ratio | $17.66 | ★ N/A |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $90.89 | $10.42 |
| 52 Week High | $124.44 | $64.80 |
| Indicator | ADUS | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 56.65 |
| Support Level | N/A | $20.61 |
| Resistance Level | $118.51 | $23.55 |
| Average True Range (ATR) | 2.97 | 1.47 |
| MACD | 0.12 | 0.07 |
| Stochastic Oscillator | 37.51 | 66.67 |
Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.